These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31556004)

  • 1. Predictors of antiproliferative effect of lanreotide autogel in advanced gastroenteropancreatic neuroendocrine neoplasms.
    Laskaratos FM; Armeni E; Shah H; Megapanou M; Papantoniou D; Hayes AR; Navalkissoor S; Gnanasegaran G; von Stempel C; Phillips E; Furnace M; Kamieniarz L; Kousteni M; Luong TV; Watkins J; Mandair D; Caplin M; Toumpanakis C
    Endocrine; 2020 Jan; 67(1):233-242. PubMed ID: 31556004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.
    Michael M; Garcia-Carbonero R; Weber MM; Lombard-Bohas C; Toumpanakis C; Hicks RJ
    Oncologist; 2017 Mar; 22(3):272-285. PubMed ID: 28220021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
    Jimenez-Fonseca P; Carmona-Bayonas A; Lamarca A; Barriuso J; Castaño A; Benavent M; Alonso V; Riesco MDC; Alonso-Gordoa T; Custodio A; Sanchez Canovas M; Hernando J; López C; La Casta A; Fernandez Montes A; Marazuela M; Crespo G; Diaz JA; Feliciangeli E; Gallego J; Llanos M; Segura A; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle J; Garcia-Carbonero R
    Neuroendocrinology; 2022; 112(1):88-100. PubMed ID: 33508849
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Lee H; Eads JR; Pryma DA
    Oncologist; 2021 Jan; 26(1):21-29. PubMed ID: 32886441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of lanreotide Autogel
    Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
    Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.
    Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Gomez-Panzani E; Ruszniewski P;
    Endocr Relat Cancer; 2016 Mar; 23(3):191-9. PubMed ID: 26743120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study.
    Caplin ME; Pavel M; Phan AT; Ćwikła JB; Sedláčková E; Thanh XT; Wolin EM; Ruszniewski P;
    Endocrine; 2021 Feb; 71(2):502-513. PubMed ID: 33052555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis.
    Kang J; Yoo C; Hwang HS; Hong SM; Kim KP; Kim SY; Hong YS; Kim TW; Ryoo BY
    Invest New Drugs; 2019 Aug; 37(4):763-770. PubMed ID: 30536151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour-to-liver ratio determined by [
    Kim YI; Yoo C; Oh SJ; Lee SJ; Kang J; Hwang HS; Hong SM; Ryoo BY; Ryu JS
    EJNMMI Res; 2020 Jun; 10(1):63. PubMed ID: 32542576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results.
    Pavel M; Ćwikła JB; Lombard-Bohas C; Borbath I; Shah T; Pape UF; Capdevila J; Panzuto F; Truong Thanh XM; Houchard A; Ruszniewski P
    Eur J Cancer; 2021 Nov; 157():403-414. PubMed ID: 34597974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.
    Buil-Bruna N; Dehez M; Manon A; Nguyen TX; Trocóniz IF
    AAPS J; 2016 May; 18(3):703-12. PubMed ID: 26908127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.
    Pavel M; Lahner H; Hörsch D; Rinke A; Denecke T; Koch A; Regnault B; Helbig D; Hoffmanns P; Raderer M
    Oncologist; 2024 May; 29(5):e643-e654. PubMed ID: 38206830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antiproliferative Effect of Somatostatin Analogs -  Data Analyses and Clinical Applications in the Context of the CLARINET Study].
    Bencsiková B
    Klin Onkol; 2016; 29(4):253-8. PubMed ID: 27534781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors.
    Diamantopoulos LN; Laskaratos FM; Kalligeros M; Shah R; Navalkissoor S; Gnanasegaran G; Banks J; Smith J; Jacobs B; Galanopoulos M; Mandair D; Caplin M; Toumpanakis C
    Neuroendocrinology; 2021; 111(7):650-659. PubMed ID: 32541155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
    Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
    Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice.
    Prasad V; Srirajaskanthan R; Toumpanakis C; Grana CM; Baldari S; Shah T; Lamarca A; Courbon F; Scheidhauer K; Baudin E; Truong Thanh XM; Houchard A; Dromain C; Bodei L
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2358-2371. PubMed ID: 32062681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Tumor Growth Rate Analysis in the Randomized CLARINET Study Establishes the Efficacy of Lanreotide Depot/Autogel 120 mg with Prolonged Administration in Indolent Neuroendocrine Tumors.
    Dromain C; Loaiza-Bonilla A; Mirakhur B; Beveridge TJR; Fojo AT
    Oncologist; 2021 Apr; 26(4):e632-e638. PubMed ID: 33393112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Study of Lanreotide Autogel in Routine Practice in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Hong Kong and Taiwan.
    Chen JS; Bai LY; Cheng HH; Chan SL; Zou JY; Shi X; Houchard A; Truong-Thanh XM; Chen MH
    Oncol Ther; 2024 Aug; ():. PubMed ID: 39215958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
    Caplin ME; Pavel M; Ćwikła JB; Phan AT; Raderer M; Sedláčková E; Cadiot G; Wolin EM; Capdevila J; Wall L; Rindi G; Langley A; Martinez S; Blumberg J; Ruszniewski P;
    N Engl J Med; 2014 Jul; 371(3):224-33. PubMed ID: 25014687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group.
    Faiss S; Pape UF; Böhmig M; Dörffel Y; Mansmann U; Golder W; Riecken EO; Wiedenmann B;
    J Clin Oncol; 2003 Jul; 21(14):2689-96. PubMed ID: 12860945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.